Clinical trials: Adjuvant Immunotherapy
Cutaneous Squamous Cell Carcinoma (CSCC)
MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer
The goal of this clinical trial is to evaluate if short-course radiation therapy (SCRT) can effectively treat high-risk cutaneous squamous cell carcinoma (cSCC) and if active surveillance is a safe alternative to radiation for…
- Trial name
- MOHSAHRTSS (NCT06998342)
- Testing
- Short course radiation, Active Surveillance
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Vermont Medical Center
Lung Cancer, Esophageal Cancer
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Background: Certain types of lung, esophageal, or thymic cancers and mesotheliomas have specific antigens (protein molecules) on their surfaces.
- Conditions
- Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma
- Trial name
- NCT01143545
- Testing
- Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant immunotherapy with chemotherapy followed by esophagectomy to determine whether additional adjuvant therapy is associated with improved…
- Conditions
- Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy
- Trial name
- NCT06056336
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Guo Xufeng
Allergy
Allergic Rhinitis, Immunotherapy and Vitamin d
Vitamin D as adjuvant to subcutaneous specific immunotherapy in patients with allergic rhinitis Specific allergen immunotherapy is the treatment of choice for patients with persistent allergic rhinitis.
- Trial name
- NCT02738619
- Testing
- Vitamin D3
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Hospital General de Mexico
Melanoma of Skin, Acral Melanoma
Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
This is a Phase II clinical trial to evaluate the efficacy and safety of perioperative toripalimab (anti-PD-1) combined with recombinant human endostatin (Endostar) as postoperative adjuvant therapy in patients with clinical…
- Conditions
- Melanoma of Skin, Acral Melanoma, Stage II Melanoma
- Trial name
- FUMS-EDJS2024 (NCT06965231)
- Testing
- Toripalimab combined with Endostar
- Where
- 4 sites in China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Stage II-IIIB(N2) Non-small Cell Lung Cancer
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
For resectable non-small cell lung cancer, neoadjuvant immunochemotherapy plus adjuvant immunotherapy or adjuvant immunochemotherapy is usually used in clinical practice.
- Trial name
- NCT06109402
- Testing
- TQB2450, Carboplatin, Pemetrexed
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Leukemia, Lymphoma, Low-Grade
Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood
This research project will focus on whether it is safe and effective to rely on donor cells to prevent relapse of leukemia, lymphoma, or other blood cancer after bone marrow stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Low-Grade, Lymphoma, Non-Hodgkin's, Multiple Myeloma
- Trial name
- NCT00143884
- Testing
- Reduced intensity conditioning, Prophylactic donor leukocyte infusions
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Michigan Rogel Cancer Center
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT06498635
- Testing
- Biospecimen Collection, Computed Tomography, Durvalumab
- Where
- 281 sites in United States
- Volunteers
- 306 people
- Sponsor
- National Cancer Institute (NCI)
Mesotheliomas Pleural
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
This is a multicentric double-blind, placebo controlled, phase III trial. In this study, patients who underwent to a surgical resection of pleural mesothelioma and are without signs of macroscopic residual disease will be…
- Trial name
- AtezoMeso (NCT04996017)
- Testing
- Atezolizumab 1200 mg in 20 ML Injection
- Where
- 19 sites in Italy
- Volunteers
- 162 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer…
- Conditions
- Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Trial name
- NCT01810913
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 342 sites in United States, Canada and 1 more
- Volunteers
- 613 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
To determine the safety and tolerability of adding durvalumab to mFOLFIRINOX prior to surgery in patients with resectable or borderline resectable pancreatic adenocarcinoma.
- Trial name
- NEO-IMPACT (NCT06094140)
- Testing
- Durvalumab, Oxaliplatin, Irinotecan
- Where
- 3 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Gastrointestinal Carcinoma, Pancreatic Cancer
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
Background: Gastrointestinal (GI) cancer affects the organs (such as the stomach, large and small intestine, pancreas, colon, liver, and biliary system) of the digestive tract.
- Conditions
- Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer, Cholangiocarcinoma
- Trial name
- NCT06690281
- Testing
- KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)
Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma
This is a multicenter, open-label, randomized phase III clinical trial evaluating perioperative treatment with sintilimab combined with chemotherapy in patients with locally advanced oral squamous cell carcinoma.
- Trial name
- NCT07371611
- Testing
- Sintilimab plus nab-paclitaxel and platinum-based chemotherapy, Radical surgery combined with radiotherapy or chemoradiotherapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Qunxing Li,MD
Primary/Relapsed Acute Lymphoblastic Leukemia (ALL) of Childhood, Adolescents and Young Adults
Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL
The aim of this clinical study is to evaluate the feasibility and safety of an individualized peptide vaccination approach in patients with acute lymphoblastic leukemia (ALL).
- Trial name
- NCT03559413
- Testing
- Individual peptide vaccination with adjuvant GM-CSF and Imiquimod
- Where
- 5 sites in Germany
- Volunteers
- 30 people
- Sponsor
- University Children's Hospital Tuebingen
Lung Cancer
Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these two treatments may kill more tumor cells.
- Trial name
- NCT00006470
- Testing
- monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody 3H1 anti-idiotype vaccine, radiation therapy
- Where
- 237 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Breast Cancer
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have…
- Trial name
- FLAMINGO-01 (NCT05232916)
- Testing
- GLSI-100
- Where
- 179 sites in United States, Belgium and 8 more
- Volunteers
- 2,250 people
- Sponsor
- Greenwich LifeSciences, Inc.
HIV Infection
Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant
HIV-specific cellular immunity is hampered in most HIV-infected individuals. Therapeutic immunization in HIV aims to strengthen the HIV-specific cellular immunity, usually in the absence of replicating HIV with antiretroviral…
- Trial name
- NCT01473810
- Testing
- Vacc-4x low dose, Vacc-4x medium dose, Vacc-4x high dose
- Where
- Norway
- Volunteers
- 24 people
- Sponsor
- Oslo University Hospital
Urothelial Carcinoma
Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
This study is an ambispective cohort observational study to analyze the efficacy of adjuvant radioimmunotherapy (radiotherapy and immunotherapy) compared with adjuvant chemotherapy in patients with the upper urinary tract…
- Trial name
- NCT06120374
- Testing
- Radiotherapy, Chemotherapy, Immunotherapy
- Where
- 3 sites in China
- Volunteers
- 178 people
- Sponsor
- Peking University First Hospital
Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1…
- Trial name
- NCT03727880
- Testing
- Pembrolizumab, Defactinib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Lei Zheng
Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
The phase III, multicenter, pragmatic PLANET trial aims to evaluate the benefit and safety of pembrolizumab as an addition to standard of care adjuvant treatment (capecitabine or olaparib) in triple negative breast cancer (TNBC)…
- Conditions
- Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative Breast Cancer, Breast Cancer Stage II
- Trial name
- PLANET (NCT07486687)
- Testing
- Standard of care plus pembrolizumab, Standard of care (capecitabine or olaparib)
- Volunteers
- 1,000 people
- Sponsor
- The Netherlands Cancer Institute